Myriad Genetics, Inc. (MYGN)
Valuation Overview•Is Myriad Genetics, Inc. Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Fragile underlying quality score of 35/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
MYGN struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company demonstrates solid revenue growth (6.7% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-46.3%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $200.4M | -1.6% | +6.7% | +8.2% | +0.9% | |
| EBITDA | -$25.3M | — | +45.7% | — | — | |
| Net Income | -$34.1M | -187.4% | -48.4% | — | — | |
| EPS (Diluted) | $-0.36 | -180.9% | — | — | — | |
| Free Cash Flow | -$21.1M | +64.1% | +55.0% | +19.2% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 70.0% | 69.5% | 70.0% | 72.0% |
| Operating Margin | -46.3% | -19.0% | -21.1% | -15.4% |
| Net Margin | -48.2% | -31.5% | -23.0% | -16.6% |
| FCF Margin | -2.5% | -10.2% | -10.6% | -1.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.06 | $-0.09 | -50.0% | ||
| Q1'26 | $-0.02 | $0.04 | +300.0% | ||
| Q4'25 | $-0.01 | $-0.13 | -1200.0% | ||
| Q3'25 | $-0.01 | $0.05 | +600.0% | ||
| Q2'25 | $-0.05 | $-0.03 | +40.0% | ||
| Q1'25 | $0.03 | $0.03 | +0.0% | ||
| Q4'24 | $0.02 | $0.06 | +215.8% | ||
| Q3'24 | $0.01 | $0.05 | +509.0% |
Total return is +3.4% (1Y), lagging the benchmark by -17.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -15.0% | -22.3% | — |
| 1Y | +3.4% | -17.5% | — |
| 3YCAGR | -38.8% | -60.5% | — |
| 5YCAGR | -30.1% | -43.4% | — |
| 10YCAGR | -16.0% | -30.9% | — |
The S&P 500 is at 30.5x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Myriad Genetics, Inc. (MYGN) valuation, health, and returns.
Based on peer relative multiples, Myriad Genetics, Inc. appears Limited: Expensive versus peers compared to industry peers.
Myriad Genetics, Inc. has multiple valuation anchors: Peer Relative Fair Value: $1.58 | Wall Street Analyst Target: $6.00 (implying +14.9% upside). A convergence of these signals offers higher conviction.
Myriad Genetics, Inc. displays weak financial health with a composite quality score of 35/100, supported by a Altman Z-Score of -0.5 (distress zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of -8.7%.
Myriad Genetics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Myriad Genetics, Inc.'s current growth trajectory is Decelerating. The company achieved -1.6% 1Y revenue growth and -180.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +6.7%.
Wall Street consensus is Hold based on 36 analysts, beating EPS expectations in 75% of recent quarters with a -1-quarter streak. The consensus price target represents a +14.9% change from current levels.
Investment risks for Myriad Genetics, Inc. include: -56.6% 1-year max drawdown, high beta (1.50x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.50x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.